[{"id":"66ccecbb-fe4e-496e-997f-7e4c2aa7798b","acronym":"","url":"https://clinicaltrials.gov/study/NCT07080242","created_at":"2025-07-26T13:29:22.344Z","updated_at":"2025-07-26T13:29:22.344Z","phase":"Phase 1","brief_title":"Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors","source_id_and_acronym":"NCT07080242","lead_sponsor":"SystImmune Inc.","biomarkers":" DLL3","pipe":"","alterations":" ","tags":["DLL3"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 120","initiation":"Initiation: 09/01/2025","start_date":" 09/01/2025","primary_txt":" Primary completion: 12/31/2027","primary_completion_date":" 12/31/2027","study_txt":" Completion: 12/31/2027","study_completion_date":" 12/31/2027","last_update_posted":"2025-07-23"},{"id":"44c07294-8489-4b3a-b2ed-b2c7e11ad982","acronym":"NCI#10057","url":"https://clinicaltrials.gov/study/NCT02978625","created_at":"2021-01-18T14:39:10.615Z","updated_at":"2025-02-25T13:48:20.165Z","phase":"Phase 2","brief_title":"Talimogene Laherparepvec and Nivolumab in Treating Patients With Refractory Lymphomas or Advanced or Refractory Non-melanoma Skin Cancers","source_id_and_acronym":"NCT02978625 - NCI#10057","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" PD-L1 • ALK • NECTIN1","pipe":" | ","alterations":" ALK positive • ALK negative","tags":["PD-L1 • ALK • NECTIN1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK positive • ALK negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Imlygic (talimogene laherparepvec) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 68","initiation":"Initiation: 09/27/2017","start_date":" 09/27/2017","primary_txt":" Primary completion: 09/01/2025","primary_completion_date":" 09/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2025-02-21"},{"id":"5b6f5e90-5c5a-4cbe-a9af-ed1c1a32c726","acronym":"","url":"https://clinicaltrials.gov/study/NCT04975152","created_at":"2021-07-23T13:52:34.008Z","updated_at":"2025-02-25T14:02:26.800Z","phase":"Phase 1","brief_title":"Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma","source_id_and_acronym":"NCT04975152","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Libtayo (cemiplimab-rwlc)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 10/22/2021","start_date":" 10/22/2021","primary_txt":" Primary completion: 06/01/2027","primary_completion_date":" 06/01/2027","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2025-02-19"},{"id":"dade1c51-e09a-44d8-a094-79a994b13e05","acronym":"Alliance A091605","url":"https://clinicaltrials.gov/study/NCT03304639","created_at":"2021-01-19T14:56:18.448Z","updated_at":"2025-02-25T16:36:59.101Z","phase":"Phase 2","brief_title":"Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma","source_id_and_acronym":"NCT03304639 - Alliance A091605","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 06/12/2018","start_date":" 06/12/2018","primary_txt":" Primary completion: 06/07/2022","primary_completion_date":" 06/07/2022","study_txt":" Completion: 09/22/2025","study_completion_date":" 09/22/2025","last_update_posted":"2025-02-06"},{"id":"42d2a0f4-bf25-41be-9b41-ecad4c959f5d","acronym":"CK-301-101","url":"https://clinicaltrials.gov/study/NCT03212404","created_at":"2021-01-18T15:50:41.447Z","updated_at":"2025-02-25T16:59:32.024Z","phase":"Phase 1","brief_title":"Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers","source_id_and_acronym":"NCT03212404 - CK-301-101","lead_sponsor":"Checkpoint Therapeutics, Inc.","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Unloxcyt (cosibelimab-ipdl)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 272","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 11/18/2021","primary_completion_date":" 11/18/2021","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-03"},{"id":"412de90b-4e3b-4146-9e47-4f34d9a4603a","acronym":"QUILT-3.055","url":"https://clinicaltrials.gov/study/NCT03228667","created_at":"2021-01-18T15:56:08.764Z","updated_at":"2025-02-25T17:35:53.589Z","phase":"Phase 2","brief_title":"QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors","source_id_and_acronym":"NCT03228667 - QUILT-3.055","lead_sponsor":"ImmunityBio, Inc.","biomarkers":" BRAF • ALK • MSI","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type","tags":["BRAF • ALK • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • MSI-H/dMMR • PD-L1 overexpression • BRAF V600 • BRAF wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • docetaxel • Bavencio (avelumab) • Anktiva (nogapendekin alfa inbakicept-pmln) • PD-L1.t-haNK"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 12/11/2018","start_date":" 12/11/2018","primary_txt":" Primary completion: 08/31/2029","primary_completion_date":" 08/31/2029","study_txt":" Completion: 12/31/2030","study_completion_date":" 12/31/2030","last_update_posted":"2025-01-29"},{"id":"a9b98e89-64a8-4245-99e7-c014eaeac52a","acronym":"KEYNOTE-B59","url":"https://clinicaltrials.gov/study/NCT04977453","created_at":"2024-02-20T21:30:41.481Z","updated_at":"2025-02-25T16:16:30.492Z","phase":"Phase 1/2","brief_title":"GI-101 As a Single Agent or in Combination with Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors","source_id_and_acronym":"NCT04977453 - KEYNOTE-B59","lead_sponsor":"GI Innovation, Inc.","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lenvima (lenvatinib) • efdelikofusp alfa (GI-101)"],"overall_status":"Recruiting","enrollment":" Enrollment 430","initiation":"Initiation: 08/02/2021","start_date":" 08/02/2021","primary_txt":" Primary completion: 10/01/2025","primary_completion_date":" 10/01/2025","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-09-19"},{"id":"607c59af-1fd9-4afc-8491-e33c116441ac","acronym":"PNeoVCA","url":"https://clinicaltrials.gov/study/NCT05269381","created_at":"2022-03-08T17:52:43.258Z","updated_at":"2024-07-02T16:34:26.810Z","phase":"Phase 1/2","brief_title":"Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05269381 - PNeoVCA","lead_sponsor":"Mayo Clinic","biomarkers":" KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK","pipe":" | ","alterations":" TMB-H","tags":["KRAS • BRAF • ALK • TMB • MSI • ROS1 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TMB-H"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • Leukine (sargramostim) • neoantigen peptide vaccine"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 03/31/2022","start_date":" 03/31/2022","primary_txt":" Primary completion: 02/24/2025","primary_completion_date":" 02/24/2025","study_txt":" Completion: 02/24/2026","study_completion_date":" 02/24/2026","last_update_posted":"2024-06-12"},{"id":"c8222add-71ac-46cf-97f8-54e3d1c741e3","acronym":"INTASYL PH-762","url":"https://clinicaltrials.gov/study/NCT06014086","created_at":"2023-08-28T14:08:35.359Z","updated_at":"2024-07-02T16:34:27.237Z","phase":"Phase 1","brief_title":"Intratumoral PH-762 for Cutaneous Carcinoma","source_id_and_acronym":"NCT06014086 - INTASYL PH-762","lead_sponsor":"Phio Pharmaceuticals Inc.","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/07/2023","start_date":" 11/07/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 09/01/2025","study_completion_date":" 09/01/2025","last_update_posted":"2024-06-11"},{"id":"4574703b-19bd-4bd3-9dd9-9adace3f6487","acronym":"","url":"https://clinicaltrials.gov/study/NCT05896839","created_at":"2023-06-09T16:06:51.642Z","updated_at":"2024-07-02T16:34:27.634Z","phase":"Phase 1/2","brief_title":"Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer","source_id_and_acronym":"NCT05896839","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • sirolimus • ABP 206 (nivolumab biosimilar)"],"overall_status":"Recruiting","enrollment":" Enrollment 16","initiation":"Initiation: 08/11/2024","start_date":" 08/11/2024","primary_txt":" Primary completion: 01/31/2027","primary_completion_date":" 01/31/2027","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-06-10"},{"id":"cd2f0c6b-9287-4ecc-b80c-c18fadf4071e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03074513","created_at":"2021-01-19T13:46:53.660Z","updated_at":"2024-07-02T16:35:03.337Z","phase":"Phase 2","brief_title":"Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors","source_id_and_acronym":"NCT03074513","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • Tecentriq (atezolizumab) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 133","initiation":"Initiation: 03/03/2017","start_date":" 03/03/2017","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/30/2025","study_completion_date":" 09/30/2025","last_update_posted":"2024-05-16"},{"id":"90bc3653-4e66-4df1-bfe9-4abee846b758","acronym":"iPRRT","url":"https://clinicaltrials.gov/study/NCT05583708","created_at":"2022-10-18T14:57:03.428Z","updated_at":"2024-07-02T16:35:09.073Z","phase":"Phase 2","brief_title":"Phase II Study of Peptide Receptor Radionuclide Therapy in Combination With Immunotherapy for Patients With Merkel Cell Cancer","source_id_and_acronym":"NCT05583708 - iPRRT","lead_sponsor":"Weill Medical College of Cornell University","biomarkers":" SSTR","pipe":"","alterations":" ","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Lutathera (lutetium Lu 177 dotatate)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 08/03/2023","start_date":" 08/03/2023","primary_txt":" Primary completion: 09/01/2026","primary_completion_date":" 09/01/2026","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2024-04-17"},{"id":"ffcba248-e63f-4a6d-8229-27993beda570","acronym":"I-MAT","url":"https://clinicaltrials.gov/study/NCT04291885","created_at":"2023-11-22T20:15:59.147Z","updated_at":"2024-07-02T16:35:09.734Z","phase":"Phase 2","brief_title":"Immunotherapy Adjuvant Trial in Patients With Stage I-III Merkel Cell Carcinoma","source_id_and_acronym":"NCT04291885 - I-MAT","lead_sponsor":"Melanoma and Skin Cancer Trials Limited","biomarkers":" TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Bavencio (avelumab)"],"overall_status":"Recruiting","enrollment":" Enrollment 132","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 04/01/2027","primary_completion_date":" 04/01/2027","study_txt":" Completion: 04/01/2028","study_completion_date":" 04/01/2028","last_update_posted":"2024-04-15"},{"id":"fc39776f-39e4-48be-8770-4ac06698638a","acronym":"NCI-2018-03329","url":"https://clinicaltrials.gov/study/NCT03798639","created_at":"2021-01-29T07:18:34.555Z","updated_at":"2024-07-02T16:35:09.957Z","phase":"Phase 1","brief_title":"Nivolumab and Radiation Therapy or Ipilimumab as Adjuvant Therapy in Treating Patients With Merkel Cell Cancer","source_id_and_acronym":"NCT03798639 - NCI-2018-03329","lead_sponsor":"Claire Verschraegen","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab)"],"overall_status":"Completed","enrollment":" Enrollment 7","initiation":"Initiation: 01/07/2019","start_date":" 01/07/2019","primary_txt":" Primary completion: 12/02/2022","primary_completion_date":" 12/02/2022","study_txt":" Completion: 12/02/2022","study_completion_date":" 12/02/2022","last_update_posted":"2024-04-12"},{"id":"2af63127-3115-4ddf-9da7-0032fefe8e92","acronym":"iPREDICT","url":"https://clinicaltrials.gov/study/NCT05013099","created_at":"2021-08-19T14:52:55.130Z","updated_at":"2024-07-02T16:35:10.176Z","phase":"Phase 2","brief_title":"Study of Zirconium Zr 89 Crefmirlimab Berdoxam PET/CT in Subjects With Advanced or Metastatic Malignancies","source_id_and_acronym":"NCT05013099 - iPREDICT","lead_sponsor":"ImaginAb, Inc.","biomarkers":" PD-L1 • KRAS • CD8 • PD-1","pipe":" | ","alterations":" PD-L1 expression • KRAS mutation • KRAS G12C • MET mutation • CD8 expression","tags":["PD-L1 • KRAS • CD8 • PD-1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • KRAS mutation • KRAS G12C • MET mutation • CD8 expression"],"overall_status":"Recruiting","enrollment":" Enrollment 80","initiation":"Initiation: 12/09/2021","start_date":" 12/09/2021","primary_txt":" Primary completion: 07/01/2025","primary_completion_date":" 07/01/2025","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2024-04-11"},{"id":"7fc864bc-2037-4926-9819-2552b751ef5d","acronym":"ATTAC-MCC","url":"https://clinicaltrials.gov/study/NCT03747484","created_at":"2021-06-30T14:53:31.876Z","updated_at":"2024-07-02T16:35:12.716Z","phase":"Phase 1/2","brief_title":"Gene-Modified Immune Cells (FH-MCVA2TCR) in Treating Patients With Metastatic or Unresectable Merkel Cell Cancer","source_id_and_acronym":"NCT03747484 - ATTAC-MCC","lead_sponsor":"Fred Hutchinson Cancer Center","biomarkers":" HLA-A","pipe":" | ","alterations":" HLA-A*02","tags":["HLA-A"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HLA-A*02"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Bavencio (avelumab) • Actimmune (interferon gamma-1 b) • MCC1 TCR"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 7","initiation":"Initiation: 07/03/2019","start_date":" 07/03/2019","primary_txt":" Primary completion: 01/10/2024","primary_completion_date":" 01/10/2024","study_txt":" Completion: 01/10/2025","study_completion_date":" 01/10/2025","last_update_posted":"2024-03-26"},{"id":"04584984-e8aa-4f15-9b71-d34c5c6cb62e","acronym":"","url":"https://clinicaltrials.gov/study/NCT03816332","created_at":"2021-01-18T18:51:19.330Z","updated_at":"2024-07-02T16:35:12.938Z","phase":"Phase 1","brief_title":"Tacrolimus, Nivolumab, and Ipilimumab in Treating Kidney Transplant Recipients With Selected Unresectable or Metastatic Cancers","source_id_and_acronym":"NCT03816332","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Yervoy (ipilimumab) • prednisone • CS1002 (ipilimumab biosimilar) • ABP 206 (nivolumab biosimilar) • CMAB 819 (nivolumab biosimilar)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 11/08/2019","start_date":" 11/08/2019","primary_txt":" Primary completion: 10/11/2022","primary_completion_date":" 10/11/2022","study_txt":" Completion: 09/22/2024","study_completion_date":" 09/22/2024","last_update_posted":"2024-03-25"},{"id":"1c3bfa16-2be9-4d09-ac41-ccb0367eba8b","acronym":"Neo-MCC","url":"https://clinicaltrials.gov/study/NCT06151236","created_at":"2023-11-30T23:17:04.030Z","updated_at":"2025-02-25T14:18:31.410Z","phase":"Phase 2","brief_title":"Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma","source_id_and_acronym":"NCT06151236 - Neo-MCC","lead_sponsor":"Melanoma Institute Australia","biomarkers":" TMB","pipe":" | ","alterations":" PD-L1 expression","tags":["TMB"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdualag (nivolumab/relatlimab-rmbw) • relatlimab (BMS-986016)"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/11/2024","start_date":" 03/11/2024","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 04/01/2034","study_completion_date":" 04/01/2034","last_update_posted":"2024-03-15"},{"id":"7edb476e-4e8d-4bde-a7cf-d599e9f2f226","acronym":"","url":"https://clinicaltrials.gov/study/NCT05076760","created_at":"2021-10-13T16:58:21.457Z","updated_at":"2024-07-02T16:35:17.029Z","phase":"Phase 1","brief_title":"MEM-288 Oncolytic Virus Alone and in Combination With Nivolumab in Solid Tumors Including Non-Small Cell Lung Cancer","source_id_and_acronym":"NCT05076760","lead_sponsor":"Memgen, Inc.","biomarkers":" EGFR • KRAS • BRAF • ALK • ROS1","pipe":" | ","alterations":" PD-L1 expression • BRAF V600E • EGFR mutation • BRAF V600 • ALK rearrangement","tags":["EGFR • KRAS • BRAF • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF V600E • EGFR mutation • BRAF V600 • ALK rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • MEM-288"],"overall_status":"Recruiting","enrollment":" Enrollment 61","initiation":"Initiation: 02/23/2022","start_date":" 02/23/2022","primary_txt":" Primary completion: 11/01/2025","primary_completion_date":" 11/01/2025","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-02-29"},{"id":"060e7871-5a8c-4f16-a224-6a753b1ca603","acronym":"","url":"https://clinicaltrials.gov/study/NCT05859074","created_at":"2023-05-15T14:04:26.274Z","updated_at":"2024-07-02T16:35:19.241Z","phase":"Phase 1","brief_title":"A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer","source_id_and_acronym":"NCT05859074","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" BRAF","pipe":" | ","alterations":" PD-L1 expression • BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • MQ710"],"overall_status":"Recruiting","enrollment":" Enrollment 56","initiation":"Initiation: 05/04/2023","start_date":" 05/04/2023","primary_txt":" Primary completion: 05/04/2028","primary_completion_date":" 05/04/2028","study_txt":" Completion: 05/04/2028","study_completion_date":" 05/04/2028","last_update_posted":"2024-02-15"},{"id":"315448b4-954b-438d-9f7e-ebc2ba97061f","acronym":"","url":"https://clinicaltrials.gov/study/NCT04902040","created_at":"2021-05-26T16:53:16.095Z","updated_at":"2024-07-02T16:35:19.388Z","phase":"Phase 1/2","brief_title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","source_id_and_acronym":"NCT04902040","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" MSI","pipe":" | ","alterations":" MSI-H/dMMR","tags":["MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Imfinzi (durvalumab) • Bavencio (avelumab) • plinabulin (BPI 2358)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 04/14/2021","start_date":" 04/14/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2025","study_completion_date":" 06/01/2025","last_update_posted":"2024-02-14"},{"id":"83a011cc-3ed7-453f-8d6a-4bfef59bfc3f","acronym":"","url":"https://clinicaltrials.gov/study/NCT03583528","created_at":"2021-01-18T17:37:43.597Z","updated_at":"2024-07-02T16:35:22.583Z","phase":"","brief_title":"DOTATOC PET/CT for Imaging NET Patients","source_id_and_acronym":"NCT03583528","lead_sponsor":"British Columbia Cancer Agency","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR positive • SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR positive • SSTR Expression"],"overall_status":"Recruiting","enrollment":" Enrollment 800","initiation":"Initiation: 07/11/2018","start_date":" 07/11/2018","primary_txt":" Primary completion: 12/31/2025","primary_completion_date":" 12/31/2025","study_txt":" Completion: 12/31/2028","study_completion_date":" 12/31/2028","last_update_posted":"2024-01-23"},{"id":"159f03cc-8156-48bf-876e-731616d2716a","acronym":"DUET-1","url":"https://clinicaltrials.gov/study/NCT05120271","created_at":"2021-11-15T12:53:36.567Z","updated_at":"2024-07-02T16:35:23.821Z","phase":"Phase 1/2","brief_title":"BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors","source_id_and_acronym":"NCT05120271 - DUET-1","lead_sponsor":"Sotio Biotech Inc.","biomarkers":" EGFR • ALK • BRCA • GPC3","pipe":" | ","alterations":" EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression","tags":["EGFR • ALK • BRCA • GPC3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK translocation • BRCA mutation • GPC3 expression • GPC3 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide • BOXR1030"],"overall_status":"Recruiting","enrollment":" Enrollment 110","initiation":"Initiation: 05/18/2022","start_date":" 05/18/2022","primary_txt":" Primary completion: 04/01/2026","primary_completion_date":" 04/01/2026","study_txt":" Completion: 12/01/2041","study_completion_date":" 12/01/2041","last_update_posted":"2024-01-11"},{"id":"e67b207c-524d-4340-9a2e-5cbef643f117","acronym":"","url":"https://clinicaltrials.gov/study/NCT04616248","created_at":"2021-01-19T20:33:34.730Z","updated_at":"2024-07-02T16:35:26.987Z","phase":"Phase 1","brief_title":"In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors","source_id_and_acronym":"NCT04616248","lead_sponsor":"University of Southern California","biomarkers":" HER-2","pipe":" | ","alterations":" PD-L1 expression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CDX-1140 • Hiltonol (poly-ICLC) • Mobista (CDX-301)"],"overall_status":"Recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 01/09/2023","start_date":" 01/09/2023","primary_txt":" Primary completion: 01/09/2025","primary_completion_date":" 01/09/2025","study_txt":" Completion: 01/09/2026","study_completion_date":" 01/09/2026","last_update_posted":"2023-12-06"}]